Does decompressive craniectomy improve functional outcomes in patients with intracerebral hemorrhage (ICH)?

Decompressive Craniectomy for Intracerebral Hemorrhage: Functional Outcomes

Decompressive craniectomy may reduce mortality in select ICH patients but does not reliably improve functional outcomes—the evidence for functional benefit remains uncertain and conflicting.

Primary Recommendation Based on Highest Quality Evidence

The 2022 AHA/ASA Guidelines provide the most authoritative guidance 1:

For mortality reduction (Class 2b, Level C-LD):

• Decompressive craniectomy with or without hematoma evacuation may be considered to reduce mortality in patients with supratentorial ICH who meet ALL of the following criteria:
  • Comatose state (GCS < 8)
  • Large hematomas (typically >30 mL) with significant midline shift
  • Elevated ICP refractory to medical management

For functional outcomes (Class 2b, Level C-LD):

• The effectiveness of decompressive craniectomy to improve functional outcomes is uncertain 1

Critical Distinction: Mortality vs. Quality of Life

This is where the evidence becomes problematic for clinical decision-making:

Mortality Benefits

• Meta-analyses and systematic reviews suggest DC offers mortality benefits, with reported mortality rates of 26% in surgical cohorts 1
• Recent meta-analysis (2026) confirms lower mortality at 30 days (OR 0.36), 90 days (OR 0.35), and overall (OR 0.33) 2
• A 2017 case-control study showed sustained survival benefits at 30 days, 6 months, and 12 months 3

Functional Outcomes—The Concerning Reality

The evidence reveals a troubling pattern: patients survive but with poor functional status

• One RCT found worse functional outcomes with DC alone (30.7% favorable) compared to hematoma evacuation alone (35.3% favorable) 1
• The 2017 case-control study explicitly states: "There was no improvement in functional outcome" despite improved survival 3
• A 2026 meta-analysis showed good neurological function (mRS 0-4) favored surgery, but no significant benefit for mRS 0-2 or mRS 0-3—meaning patients survived but remained severely disabled 2
• The pooled favorable outcome rate was only 53% in systematic reviews 1

Evidence Contradictions and Nuances

When DC combined with hematoma evacuation:

• One RCT showed improved outcomes (70% vs 20% favorable) when DC plus expansive duraplasty was added to hematoma evacuation 1
• However, a 2026 systematic review found no significant benefit when adding DC to hematoma evacuation (RR 0.88 for favorable outcomes) 4
• A 2026 single-center study found no independent association between DC and 90-day outcomes after adjusting for baseline severity 5

The confounding by indication problem:

• Patients selected for DC have more severe disease at baseline—larger hematomas, worse GCS, greater midline shift 6, 5
• Crude outcomes appear worse in DC groups, but this reflects selection bias rather than treatment effect 5

Clinical Algorithm for Decision-Making

Step 1: Assess if patient meets criteria for consideration

• GCS < 8 (comatose)
• Hematoma volume >30 mL
• Significant midline shift (typically >5-10 mm)
• ICP elevation refractory to medical management (osmotic therapy, sedation, head elevation)

Step 2: If criteria met, consider DC primarily as a life-saving measure

• Understand that you are likely reducing mortality but NOT improving functional independence
• Most survivors will have mRS 4-6 (moderate-severe disability to death)

Step 3: Goals of care discussion is MANDATORY

• Explicitly discuss with family that survival may come with severe disability
• DC should generally be avoided if patient's pre-morbid wishes indicated preference for quality over quantity of life
• Consider whether patient would accept survival with severe dependency (requiring assistance for all activities)

Step 4: If proceeding with surgery

• DC combined with hematoma evacuation may be preferable to DC alone based on limited RCT data 1
• Expansive duraplasty should be considered if performing DC 1

Common Pitfalls to Avoid

1. Performing DC solely to "do something" without realistic outcome expectations—most patients will not achieve functional independence
2. Failing to have goals of care discussions before surgery when patient is comatose
3. Assuming mortality benefit equals meaningful recovery—the evidence clearly separates these outcomes
4. Operating on patients with smaller hematomas (<30 mL) where benefit is even less established 1
5. Ignoring the cost: Longer hospital stays (median 30 vs 7 days) and higher complication rates (76% vs 33%) 3

The Bottom Line for Real-World Practice

Decompressive craniectomy is a life-prolonging intervention, not a function-restoring one. The 2022 AHA/ASA Guidelines appropriately give it a Class 2b recommendation (may be considered) with explicit acknowledgment that functional benefit is uncertain 1.

In the context of prioritizing quality of life as the primary outcome, DC should be approached with significant caution and reserved for patients whose values clearly prioritize survival over functional independence. The Swedish multi-center study showing 40% favorable outcomes 6 represents highly selected populations and should not be generalized.

The ongoing SWITCH trial may provide better evidence, but until then, honest prognostication about likely severe disability is ethically mandatory before proceeding with DC for ICH 1.